This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Access Consortium Procedure
Access Consortium Procedure
The Access Consortium Procedure is a collaborative initiative by regulatory authorities from several countries (e.g. Australia (Therapeutic Goods Administration, TGA); Canada (Health Canada); Singapore (Health Sciences Authority, HSA); Switzerland (Swissmedic); United Kingdom (Medicines and Healthcare products Regulatory Agency, MHRA). The objective is to streamline and align regulatory processes, ensuring quicker patient access to safe and effective medicines. It involves sharing information and resources among member countries to improve drug approval efficiency.